Heart transplant is the gold standard option for heart failure (HF) patients when all other options fail, says a cardiologist and heart failure specialist at the recent APSC 2017 Congress, with excellent long-term outcomes.
Lower total cholesterol-to-high density lipoprotein cholesterol ratio (TC:HDL) and low-density lipoprotein (LDL) levels appear to be associated with elevated mortality rates in patients with acute coronary syndrome (ACS), according to a study presented at the 21st Asian Pacific Society of Cardiology Congress (APSC 2017) held in Singapore.
Nonvitamin K antagonist (non-VKA) oral anticoagulants (NOACs) offer better outcomes than VKAs in Asian patients for the prevention of atrial fibrillation (AF)-associated stroke, according to data presented at the Asian Pacific Society of Cardiology Congress (APSC) 2017 held in Singapore.
Short-term use (<30 days) of the anticoagulant warfarin following bioprosthetic aortic valve replacement (AVR) reduced the incidence of major adverse cardiovascular events (MACE) but not the risk of bleeding and re-operation, while long-term warfarin use (31–90 days) resulted in a higher incidence of MACE and reoperation, according to data presented at the Asian Pacific Society of Cardiology Congress (APSC 2017) held in Singapore.
Reduction of resting heart rate (RHR) with the beta-blocker (β-blocker) bisoprolol was associated with a decreased incidence of composite cardiovascular (CV) events in Chinese patients with coronary artery disease (CAD) according to a study presented at the Asian Pacific Society of Cardiology Congress (APSC 2017) held in Singapore.
Remodeling of the left atrium continues into middle and old age as a form of haemodynamic compensation for alterations in the structure and function of the heart, according to a study presented at the recently concluded 21st Asian Pacific Society of Cardiology Congress (APSC 2017).
Elvira Manzano, Roshini Claire Anthony,
01 Oct 2019
The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.
Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.
Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]